AMP®AIM is a collaboration of experts from a range of scientific disciplines working together to expand researchers understanding of the cellular and molecular interactions that lead to inflammation and autoimmune disease.
The Accelerating Medicines Partnership® Autoimmune and Immune-Mediated Disease Program (AMP AIM) was launched in 2021 as a collaboration between the National Institutes of Health (NIH), the Foundation for the National Institutes of Health (FNIH), pharmaceutical companies, and nonprofit organizations. AMP AIM researchers focus on psoriatic spectrum disorder (PSD), rheumatoid arthritis (RA), Sjögren’s disease (SjD), and systemic lupus erythematosus (SLE).
AMP AIM was created to expand and advance an earlier program known as AMP RA/SLE (focused only on rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)). Both AMP AIM and AMP RA/SLE originate from the Accelerating Medicines Partnership (AMP) collaboration between the NIH, U.S. Food and Drug Administration, pharmaceutical companies, and nonprofit organizations created in 2014.
The AMP AIM Program will focus on identifying common inflammatory pathways in psoriatic spectrum disorder (PSD), rheumatoid arthritis (RA), Sjögren’s disease (SjD), and systemic lupus erythematosus (SLE). To accomplish this, experts apply novel and high dimensional research tools to identify cellular and molecular disease pathways that cause inflammation, injury, abnormal function, and clinical disease.
The goal of the AMP AIM Program is to apply knowledge gained from these studies to advance and improve the development of new treatments for autoimmune disease. Additionally, the AMP AIM Project will work to create new research and computational tools, data storage platforms, and data sharing technologies, with the overall goal of enhancing the accessibility and ease of analysis of autoimmune disease biological data.